Agilent Technologies, Inc. (NYSE:A) VP Mark Doak sold 4,154 shares of the stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $67.00, for a total transaction of $278,318.00. Following the completion of the sale, the vice president now owns 68,270 shares in the company, valued at $4,574,090. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Agilent Technologies, Inc. (A) traded down $0.41 during trading hours on Wednesday, hitting $65.83. 2,383,900 shares of the company traded hands, compared to its average volume of 1,864,988. Agilent Technologies, Inc. has a twelve month low of $44.11 and a twelve month high of $70.93. The company has a quick ratio of 2.85, a current ratio of 3.30 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $21,317.89, a PE ratio of 27.95, a PEG ratio of 2.00 and a beta of 1.27.

Agilent Technologies (NYSE:A) last released its earnings results on Monday, November 20th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Agilent Technologies had a net margin of 15.30% and a return on equity of 16.96%. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the business earned $0.59 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis. research analysts predict that Agilent Technologies, Inc. will post 2.58 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 2nd will be given a dividend of $0.149 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.91%. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. The ex-dividend date of this dividend is Friday, December 29th. Agilent Technologies’s payout ratio is 25.24%.

Several brokerages have commented on A. BidaskClub downgraded shares of Agilent Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 12th. Jefferies Group restated a “buy” rating and set a $66.00 target price on shares of Agilent Technologies in a report on Wednesday, August 9th. Deutsche Bank set a $68.00 target price on shares of Agilent Technologies and gave the stock a “buy” rating in a report on Wednesday, August 16th. Janney Montgomery Scott raised their target price on shares of Agilent Technologies from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, August 16th. Finally, Robert W. Baird restated a “buy” rating and set a $70.00 target price on shares of Agilent Technologies in a report on Friday, October 20th. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Agilent Technologies currently has a consensus rating of “Buy” and an average price target of $68.34.

A number of hedge funds have recently added to or reduced their stakes in A. Dupont Capital Management Corp bought a new stake in shares of Agilent Technologies in the third quarter valued at about $101,000. Balentine LLC boosted its position in shares of Agilent Technologies by 2.9% in the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after acquiring an additional 50 shares during the period. Sun Life Financial INC boosted its position in shares of Agilent Technologies by 26,144.4% in the second quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock valued at $140,000 after acquiring an additional 2,353 shares during the period. Acrospire Investment Management LLC boosted its position in shares of Agilent Technologies by 92.3% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock valued at $148,000 after acquiring an additional 1,200 shares during the period. Finally, Parallel Advisors LLC boosted its position in shares of Agilent Technologies by 5.3% in the second quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock valued at $157,000 after acquiring an additional 131 shares during the period.

COPYRIGHT VIOLATION NOTICE: “Mark Doak Sells 4,154 Shares of Agilent Technologies, Inc. (A) Stock” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/06/mark-doak-sells-4154-shares-of-agilent-technologies-inc-a-stock.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Insider Buying and Selling by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.